Gilead Sciencees today
As of 02/21/2025 04:00 pm
- 52 weeks
- $ 62.07
▼
111.03 dollars
- Profit
- 2.80 %
- P/E ratio.
- 297.16
- The target price
- 102.08 dollars
Gilead Sciences Inc. Nasdaq: Gild The stocks rose to the highest new level in 52 weeks at 106.69 dollars recently in the fourth quarter of the 2024 profits. After sleeping for many years, the stock finally found benefit again, as it did not look at the price levels in a decade. The medical sector company was mostly known in the main current due to its direct controversy that included Soucaldi in 2013, its treatment of $ 84,000 for hepatitis C (HEP C).
The treatment for 12 weeks was the first treatment in the world of the world, but the cost made the cost exorbitant even for those who had health insurance. Ultimately, the controversy faded more than $ 1,000 per birth control pills after achieving financing in the Senate and new competition from Abbvie Inc. Nyse: abbv Direct antivirals (DAAS) in the following years.
Gilead defended its prices as the highest in the world at the time by saying that long -term cost savings from HEP C treatment have been far out of the elimination of the disease. Here are 4 reasons because Gilead Sciences has a much more space.
1) Gilead reported strong profits and raised directives
Gilead Sciences today
102.08 dollars
Moderate purchase
Based on 29 analyst classifications
| High expectations | 125.00 dollars |
|---|---|
| Average expectations | 102.08 dollars |
| Low expectations | $ 69.00 |
Gilead Sciences
In the Q4 2024 profit report, Gilead has published an in principle of $ 1.90 per share, over 16 cents. Revenue grew by 7 % year on an annual basis to $ 7.57 billion, crushing unanimity estimates of $ 7.15 billion. The increase was driven by increasing products sales and lower search and development expenses in the process. The margin of the total product increased to 79 % in the fourth quarter, compared to 70 % in the previous year. The company produced $ 3 billion of operating cash flow and closed the year with $ 10 billion in cash and cash rewards.
Gilead has issued emerging instructions for the full year 2025 from the share profitability between $ 7.70 and $ 8.10, overcoming the unanimity estimates of $ 7.61. Product sales are expected to range between $ 28.2 billion and 28.6 billion dollars, including VEKLURY sales of $ 1.4 billion, which is the Covid-19 treatment.
2) HIV concession continues in HIV, oncology, and liver disease concession in growth
In 2024, Gilead has recorded 8 % on year on an annual basis to 19.6 billion dollars in HIV sales, driven by high demand and average rate of achieved price. Biktarvy sales increased by 13 % year on an annual basis to $ 13.4 billion, driven by increasing demand. Descovy sales increased by 6 % to $ 2.1 billion, also driven by increasing demand. Selling liver wallet sales increased by 9 % year on an annual basis to $ 3 billion. TRODEVY breast cancer treatment increased by 24 % year on year to $ 1.3 billion, driven by increasing demand in all regions. Gilead Yesarta and Tecartus increased by 5 % and 9 %, respectively.
3) Gilead HIV vaccine is 100 % effective and will be launched in the summer of 2025.
Gilead has achieved a mutation in the treatment of HIV with Lenacapavir, which was 100 % in the purpose of 1 and 99.9 % in studies 2 in the prevention of HIV. Lenacapavir, an antiviral drug that was sold under the name of the Sunlenca brand, was approved for the treatment of HIV-1 drug-resistant drugs.
The company has submitted a new drug request to the FDA to treat Lenacapavir twice annually to prevent HIV in late December 2024. Its name is the science magazine in the name of 2024, penetration of the year. The drug was granted the case of FDA (BTD) treatment to accelerate the approval. Gilead is expected to launch in the United States in the summer of 2025 and in Europe by the end of 2025.
4) GILD is a bull science
The bull science pattern consists of two parts. First, the flag is considered a high -end upward step in the arrows that ends at its peak. Then, science constitutes uniformity with parallel trend lines. This pattern is confirmed when the arrow is separated over the upper direction line and exceeds the peak of the flag.
GILD caused the daily collapse of the bull science on the gap through $ 96.28 after beating the fourth quarter. The upper gap fills the support at $ 100.83. Gilde reached a height of 52 weeks at $ 106.69 before declining. The target consensus price is 101.33 dollars, with the highest analyst at $ 125.00.
VWAP support daily decree is $ 96.07, and the daily RSI began to slip at 68 domains. FIB decline support levels are 101.53 dollars, 96.81 dollars, 92.87 dollars and $ 89.15.
The upscale investors can think about using FIB withdrawals to buy DIP. If the shares are set, the writing of the call covered with the ups of the ups of the fibs implement the wheel strategy for income as well as the annual profit revenue by 2.96 %.
Before you think about Gilead Sciences, you will want to hear it.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts are quietly whispered to their customers to buy now before wiping the broader market … and Gilead Sciences was not in the list.
While Gilead Sciences currently has a “moderate purchase” classification among analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
I wonder where to start (or end) with artificial intelligence shares? These ten simple stocks can help investors build a long -term wealth as artificial intelligence continues to grow to the future.
